NCT05822674

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

A Preliminary Clinical Study on the Effects of Oral Hypoglycemic Agents on the Stress Hyperglycemic Ratio in Type 2 Diabetes Patients in the Absence of Serious Illness

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: University of Diyala · Academic / Other
• Sex: All
• Age: 35 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications

Detailed description

Stress hyperglycemia (SH) is an increase in circulating glucose levels in biological fluids as a physiological response to stress in diabetic patients who are known or newly diagnosed, or a pathological condition associated with in-hospital-related hyperglycemia. Interventions. Through their pleiotropic effects, some oral hypoglycemic agents improved stress hyperglycemia. When compared to non-SGLT-I (sodium glucose transporter-inhibitor) users, diabetic patients who used (SGLT-I) and had an acute myocardial infarction had less prevalent stress hyperglycemia, a smaller infarct size, and evidence of a low inflammatory response. The rationale this study is to evaluate the SHR in T2D patients who do not have serious illnesses and are managed with oral hypoglycemic agents

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Sitagliptin/metformin ( 50/500mg) Oral Tablet	The drug was prescribed once daily per oral for 10 weeks
DRUG	Empagliflozin/metformin(10/500mg) Oral Tablet	The drug was prescribed once daily per oral for 10 weeks

Timeline

• Start date: 2022-01-01
• Primary completion: 2022-12-31
• Completion: 2023-02-01
• First posted: 2023-04-21
• Last updated: 2023-04-21

Locations

1 site across 1 country: Iraq